Gilead Sciences Inc is to spend $405 million to acquire MiroBio Ltd, a 2019 University of Oxford spin-out, which has developed a group of medicines designed to restore balance to the immune system. The technology is based on antibodies that stimulate immune inhibitory receptors in order to suppress inflammation. The target diseases are autoimmune disorders.
